Preferred Label : moxisylyte;
MeSH definition : An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used
locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic
agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312);
MeSH synonym : acetoxythymoxamine; thymoxamine; thymoxyalcylamine;
CISMeF synonym : viatris brand of moxisylyte hydrochloride; hansam brand of moxisylyte hydrochloride; arkopharma brand of moxisylyte hydrochloride;
DeCS synonym : Carlyt ne;
MeSH hyponym : carlytène; moxisylyte hydrochloride; opilon brand of moxisylyte hydrochloride; icavex; Hydrochloride, Moxisylyte;
MeSH CAS label : phenol, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)-, acetate (ester);
MeSH Related Number : 54-32-0 (Moxisylyte); moxisylyte hydrochloride; WK2KZM9V6X;
Registry Number MeSH : 54-32-0;
Related CAS MeSH : WK2KZM9V6X (Moxisylyte hydrochloride);
Codes EINECS : 200-204-1;
Is substance : O;
UNII : PW8QYA7KI0;
InChIKey : VRYMTAVOXVTQEF-UHFFFAOYSA-N;
Origin ID : D013948;
UMLS CUI : C0040108;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Currated CISMeF NLP mapping
Fils d'après SNOMED CT
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
- NMI 221 [MeSH Supplementary Concept]
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used
locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic
agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/carlytene_02-11-2011_avis_ct-11263.pdf
http://www.has-sante.fr/portail/jcms/c_1121578/carlytene
2011
France
French
administration, oral
treatment outcome
insurance, health, reimbursement
moxisylyte
moxisylyte hydrochloride
vasodilator agents
moxisylyte
cognition disorders
aged
raynaud disease
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-4905_carlytene.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_618878
2007
France
French
moxisylyte
insurance, health, reimbursement
administration, oral
cognition disorders
aged
raynaud disease
vasodilator agents
moxisylyte
tablets
evaluation of the transparency committee
---